Methodology v4.1 scores telehealth GLP-1 programs out of 100 across seven weighted categories. It replaced our earlier six-criterion rubric on October 16, 2026.
| Category | Points | What we check |
|---|---|---|
| Pricing transparency | 20 | Is a full price list published, per plan length, with the billing basis (by the month, every 4 weeks, prepaid) and any membership stated? |
| Total annual cost | 20 | What does a year cost at a maintenance dose, counting memberships, 13-cycle billing and the end of first-month or sale prices? |
| Clinical oversight | 15 | Is the prescribing clinician type stated, is a medical director named, and does the intake ask the safety questions on the FDA labels? |
| Pharmacy transparency | 15 | Does the program name the pharmacy that fills the prescription, its location and whether it is a 503A pharmacy or a 503B outsourcing facility? |
| Support | 10 | What follow-up, messaging, coaching and side-effect support is included, and how is it reached? |
| Regulatory disclosure | 10 | Does the program say plainly that compounded drugs are not FDA-approved, avoid implying they are the brand product, and disclose its terms? |
| Accessibility | 10 | States served, payment options (FSA/HSA, installments), cancellation terms and how easy it is to stop. |
What evidence do we use?
We score from what a program publishes on its own pages, read on a dated visit, plus public records (FDA warning letters, state licensing, NPPES). Prices come from the seller's own pricing pages; when a page cannot be read we carry the earlier figure with its date and mark it "reported" rather than estimate. We do not run test purchases, and we no longer claim weekly checkout observations.
Which price checks do we apply?
On price pages we apply five checks: billed by the month, medication and care in one price, the same price at every dose, no membership, and a first-party read. A program can pass all five and still not be the lowest price; we show both.
Current scores
NexLife scores 94/100 under v4.1 and is our editor's pick. Other providers were scored in our July 2026 review under the earlier six-criterion rubric (pricing transparency 25, pharmacy 20, clinical 15, regulatory 15, patient experience 15, evidence 10); those scores are labelled "July 2026 review (six-criterion rubric); v4.1 re-score pending", and the providers are listed alphabetically without rank numbers until they are re-scored.
What changed from the earlier rubric?
The earlier rubric gave full credit for "dual 503A and 503B" pharmacy partners, "semaglutide base API", LegitScript certification and "Quest/Labcorp lab integration", and our July pages scored NexLife on those items. NexLife's own pages do not support several of them, so the items were dropped and NexLife's score was recalculated under v4.1. GLPOneMedical is affiliate-supported by NexLife; see the conflicts-of-interest page.
Who researches and reviews our pages?
- Dr. Parmis — Medical Researcher, Western University of Health Sciences. Researches and writes our pages, reads the primary sources and keeps the data files current.
- Dr. Jonathan Snipes, MD — medical reviewer (NPI 1821250077).
- Kim Callender, NP (FNP-BC) — medical reviewer (NPI 1144661760).
Each page shows when it was released and when it was last reviewed, and the author block names who researched and reviewed it. You can check both NPI numbers in the public NPPES registry.